STAAR recruits a new leading star

Article

Barry G. Caldwell has been named as the new President and Chief Executive Officer of STAAR Surgical.

Barry G. Caldwell has been named as the new President and Chief Executive Officer of STAAR Surgical.

Mr Caldwell was previously President and CEO of IRIDEX Corporation where, during his two year tenure, he helped grow direct ophthalmic sales by more than 20%. He has also served in various leadership capacities with Alcon, CooperVision and Cavitron and has been a board member for Tekia and Laser Diagnostic Technologies, now part of Carl Zeiss Meditec.

Mr Caldwell replaces David Bailey who has now been named President of STAAR Surgical International Operations.

Recent Videos
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
Related Content
A black-and-white image of a woman placing her hand over her eye, as if in pain. A red glow on her eye area indicates she is experiencing neuropathic corneal pain. Image credit: ©mykolasamoilenk – stock.adobe.com

OKYO Pharma files US FDA Fast Track application for neuropathic corneal pain treatment urcosimod

Martin David Harp
March 11th 2025
Article

Urcosimod, formerly known as OK-101, showed clear statistical significance in multiple endpoints in a recently completed Phase 2 trial

Higher molar dose and its translation into clinical practice. Led by John Kitchens, MD; Joined by Peter Kaiser, MD

Higher Molar Dose and Its Translation into Clinical Practice

John Kitchens, MD;Peter Kaiser, MD
July 22nd 2024
Podcast
Sun rays stretch over the horizon as a sun rises or sets against a blue sky. Image credit: ©Pavlo Vakhrushev – stock.adobe.com

Experts say revakinagene taroretcel-lwey approval may represent dawn of new treatments for neurodegenerative conditions

Sheryl Stevenson;Anat Loewenstein, MD, MHA;Rishi P. Singh, MD;Martin Friedlander, MD, PhD;Mohammad Rafieetary, OD, FAAO
March 10th 2025
Article

Clinicians react to the US approval of revakinagene taroretcel-lwey (Encelto; Neurotech Pharmaceuticals) for macular telangiectasia type 2

A close-up of an elderly patient's face. They are administering eye drops. Image credit: ©photocrew – stock.adobe.com

Nicox SA shares research findings from NCX 470 Mont Blanc Phase 3 glaucoma trial

Jordana Joy
March 7th 2025
Article

The novel nitric oxide-donating bimatoprost eye drop is designed to lower IOP in patients with open-angle glaucoma or ocular hypertension

The Heidelberg Congress Center in Heidelberg, Germany. Image courtesy of Heidelberg Engineering.

Heidelberg Engineering announces two-day International SPECTRALIS Symposium

Hattie Hayes
March 7th 2025
Article

The event will include presentations on artificial intelligence, ocular imaging and surgical topics

An illustration shows women and girls representing different nationalities and ethnicities. Image credit: ©DisignUA – stock.adobe.com

The Fred Hollows Foundation issues a call to action for International Women's Day

Sheryl Stevenson
March 6th 2025
Article

The Australia-based organisation is partnering with the UN Friends of Vision group for an event on 11 March

© 2025 MJH Life Sciences

All rights reserved.